Compare · BMRA vs IDXX
BMRA vs IDXX
Side-by-side comparison of Biomerica Inc. (BMRA) and IDEXX Laboratories Inc. (IDXX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BMRA and IDXX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- IDXX is the larger of the two at $43.60B, about 8349.0x BMRA ($5.2M).
- Over the past year, BMRA is down 44.3% and IDXX is down 14.5% - IDXX leads by 29.8 points.
- IDXX has been more active in the news (6 items in the past 4 weeks vs 2 for BMRA).
- IDXX has more recent analyst coverage (23 ratings vs 1 for BMRA).
- Company
- Biomerica Inc.
- IDEXX Laboratories Inc.
- Price
- $1.76+0.28%
- $548.88-0.79%
- Market cap
- $5.2M
- $43.60B
- 1M return
- +6.33%
- -3.69%
- 1Y return
- -44.32%
- -14.49%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1991
- News (4w)
- 2
- 6
- Recent ratings
- 1
- 23
Biomerica Inc.
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
IDEXX Laboratories Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Latest BMRA
- Biomerica Announces $2.23 Million Financing
- Biomerica Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Biomerica Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development
- ConsumerDirect Expands Executive Team with Appointment of Gary Lu, CPA as Chief Financial Officer
- Citizens initiated coverage on Biomerica with a new price target
- Biomerica's inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026
- Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway
- Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs
- Biomerica Reports Third Quarter Fiscal 2026 Financial Results
Latest IDXX
- EVP, CFO and Treasurer Emerson Andrew exercised 265 shares at a strike of $178.26 and covered exercise/tax liability with 86 shares, increasing direct ownership by 4% to 4,421 units (SEC Form 4)
- IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test
- SEC Form 10-Q filed by IDEXX Laboratories Inc.
- IDEXX Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- IDEXX Laboratories Announces Second Quarter Results
- Director Hooley Joseph L was granted 49 shares, increasing direct ownership by 18% to 325 units (SEC Form 4)
- IDEXX Releases 2025 Corporate Responsibility Report, Highlighting Progress Against Its Goals
- IDEXX Laboratories to Release 2026 Second Quarter Financial Results
- Executive Vice President Fennell George converted options into 639 shares and covered exercise/tax liability with 284 shares, increasing direct ownership by 4% to 10,433 units (SEC Form 4)
- SEC Form SD filed by IDEXX Laboratories Inc.